Brief: FDA Confirms Withdrawal Of Oncopeptides' Pepaxto From US Market
Feb 23 (Reuters) - Oncopeptides AB ONCO.ST :
* ONCOPEPTIDES RECEIVES DECISION FROM THE U.S. FOOD AND DRUG ADMINISTRATION CONFIRMING
WITHDRAWAL
OF PEPAXTO FROM THE U.S. MARKET
* FDA CONCLUDES THAT THEY HAVE DETERMINED THAT GROUNDS FOR WITHDRAWING APPROVAL HAVE BEEN
MET
* WILL NOW THOROUGHLY ASSESS DECISION
Source text for Eikon: ID:nMFN8nxyvy
Further company coverage: ONCO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy